UK AI drug discovery startup raises $140m with Nvidia, Anthropic
Basecamp Research, a London-based life sciences firm using AI to accelerate drug development, has secured $140m in funding. The round includes participation from Nvidia and first-time investor Anthropic, both major players in AI. The startup focuses on treating diseases by speeding up the discovery of new medicines.
“The involvement of Anthropic alongside Nvidia signals growing convergence between AI model builders and applied biotech, a trend to watch as compute-heavy startups seek strategic backers.”
What it means
Basecamp’s funding round reflects broader investor interest in AI-driven drug discovery, a sector that has seen mixed results despite high valuations. The participation of two AI infrastructure giants suggests confidence in the startup’s technical approach, but whether this translates into faster clinical outcomes remains unproven. Future milestones—like pipeline advancements or regulatory progress—will determine if this round is a bet on the company or the sector itself.
Read the original reporting
The outlets below did the original reporting.
Related briefs
- HIFI raises $37M to bridge banking and stablecoins
- DeepSeek hits $1B run rate, raises at $7.5B valuation
- Maven Robotics reportedly deploys humanoid robots in UK factory pilot
- Nscale raises $3.36B in pre-IPO convertible notes amid IPO filing
- AI agents may force enterprises to rethink trust—Ekai raises $1.7M
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.